✦ LIBER ✦

Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression

✍ Scribed by Stein, Dan J; Picarel-Blanchot, Francoise; Kennedy, Sidney H

Book ID: 120344675
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 152 KB
Volume: 28
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.2294

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.2.c.001 Efficacy of the novel antidepr

P.2.c.001 Efficacy of the novel antidepressant agomelatine for anxiety symptoms within depression

✍ D.J. Stein; S.H. Kennedy 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

P.2.c.017 Antidepressant efficacy of ago

P.2.c.017 Antidepressant efficacy of agomelatine in major depressive disorder:meta-analysis of three pivotal studies

✍ S.A. Montgomery; J.P. Olie; S.H. Kennedy 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 73 KB

P.2.c.038 Long-term efficacy of agomelat

P.2.c.038 Long-term efficacy of agomelatine, a novel antidepressant, in the prevention of relapse in out-patients with major depressive disorder

✍ G.M. Goodwin; F. Rouillon; R. Emsley 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 70 KB

The efficacy profile of vilazodone, a no

The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

✍ Reed, Carol R.; Kajdasz, Daniel K.; Whalen, Heidi; Athanasiou, Maria C.; Gallipo 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 407 KB

Economic evaluation of agomelatine relat

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

✍ Nikos Maniadakis, Georgia Kourlaba, Theodoros Mougiakos… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 383 KB

Impact of the novel antidepressant agome

Impact of the novel antidepressant agomelatine on disturbed sleep–wake cycles in depressed patients

✍ Maria-Antonia Quera-Salva; Patrick Lemoine; Christian Guilleminault 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## Background Disturbance of sleep–wake cycles is common in major depressive disorder (MDD), usually as insomnia, but also as hypersomnia or reduced daytime alertness. Agomelatine, an MT~1~ and MT~2~ receptor agonist and 5‐HT~2C~ receptor antagonist, represents a novel approach in MDD,